These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26544664)

  • 1. Response to the Letter by Kalra S. et al.
    Kramer CK; Zinman B; Retnakaran R
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L118. PubMed ID: 26544664
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
    Kalra S; Gupta Y
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L116-7. PubMed ID: 26544663
    [No Abstract]   [Full Text] [Related]  

  • 3. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide and cardiovascular outcomes in type 2 diabetes.
    Jones B
    Ann Clin Biochem; 2016 Nov; 53(6):712. PubMed ID: 28071177
    [No Abstract]   [Full Text] [Related]  

  • 5. Increase in cortisol/ACTH ratio after chronic treatment with liraglutide in patients with type 2 diabetes.
    Kamei S; Kaneto H; Tanabe A; Kinoshita T; Obata A; Kimura T; Hirukawa H; Tatsumi F; Shimoda M; Kohara K; Anno T; Nakanishi S; Mune T; Kaku K
    Diabetes Metab; 2017 Sep; 43(4):398-399. PubMed ID: 28283288
    [No Abstract]   [Full Text] [Related]  

  • 6. Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Sep; 59(1529):147-149. PubMed ID: 28880845
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
    Tanabe A; Kaneto H; Kamei S; Hirukawa H; Shimoda M; Kimura T; Obata A; Okauchi S; Tatsumi F; Kohara K; Mune T; Kaku K
    J Diabetes Complications; 2016 Aug; 30(6):1201-3. PubMed ID: 27220544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Fischli S; Henzen C
    Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
    [No Abstract]   [Full Text] [Related]  

  • 9. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
    Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
    G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis.
    Tassone F; Baffoni C; Gianotti L; Pellegrino M; Magro G; Cesario F; Maccario M; Borretta G
    Minerva Endocrinol; 2015 Dec; 40(4):331-2. PubMed ID: 25801016
    [No Abstract]   [Full Text] [Related]  

  • 11. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
    Jacobsen LV; Flint A; Olsen AK; Ingwersen SH
    Clin Pharmacokinet; 2016 Jun; 55(6):657-72. PubMed ID: 26597252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):154-158. PubMed ID: 29350569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
    Kajiwara M; Tanaka A; Kawasaki T; Nakao K; Sakamoto T; Toyoda S; Inoue T; Koga N; Node K
    J Cardiol; 2017 Mar; 69(3):511-517. PubMed ID: 27894787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
    Geurin MD
    Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2729-2733. PubMed ID: 28472325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [in process].
    Reisdorf S
    Med Monatsschr Pharm; 2017 Jan; 40(1):34-5. PubMed ID: 29952534
    [No Abstract]   [Full Text] [Related]  

  • 19. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of liraglutide on endothelial function in patients with type 2 diabetes.
    Nandy D; Johnson C; Basu R; Joyner M; Brett J; Svendsen CB; Basu A
    Diab Vasc Dis Res; 2014 Nov; 11(6):419-30. PubMed ID: 25212693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.